Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities research analysts at Leede Financial raised their FY2026 EPS estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, August 6th. Leede Financial analyst D. Loe now expects that the company will post earnings of ($0.20) per share for the year, up from their previous estimate of ($0.24). The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.33) per share. Leede Financial also issued estimates for Cardiol Therapeutics' FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.18) EPS and FY2029 earnings at $0.23 EPS.
Separately, HC Wainwright began coverage on shares of Cardiol Therapeutics in a report on Monday, June 2nd. They set a "buy" rating and a $9.00 price objective on the stock.
Read Our Latest Report on Cardiol Therapeutics
Cardiol Therapeutics Stock Performance
NASDAQ:CRDL opened at $0.99 on Monday. The firm's 50-day moving average is $1.36 and its 200-day moving average is $1.21. Cardiol Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.26 and a current ratio of 3.26. The company has a market cap of $81.51 million, a price-to-earnings ratio of -2.90 and a beta of 1.05.
Institutional Trading of Cardiol Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Thompson Davis & CO. Inc. bought a new stake in Cardiol Therapeutics in the second quarter valued at about $39,000. Cetera Investment Advisers bought a new stake in Cardiol Therapeutics in the fourth quarter valued at about $56,000. Envestnet Asset Management Inc. bought a new stake in Cardiol Therapeutics in the fourth quarter valued at about $398,000. Lion Street Advisors LLC increased its stake in Cardiol Therapeutics by 8.5% in the first quarter. Lion Street Advisors LLC now owns 333,725 shares of the company's stock valued at $318,000 after acquiring an additional 26,059 shares during the period. Finally, PVG Asset Management Corp bought a new stake in Cardiol Therapeutics during the fourth quarter worth about $624,000. Institutional investors own 12.49% of the company's stock.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.